The price of Lilly(Eli) & Co (NYSE:LLY) shares last traded on Wall Street fell -4.49% to $591.32.
Based on available information, 30 analysts follow Lilly(Eli) & Co (NYSE:LLY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $722.00 and a low of $430.00, we find $650.00. Given the previous closing price of $619.13, this indicates a potential upside of 4.99 percent. LLY stock price is now 3.18% away from the 50-day moving average and 31.04% away from the 200-day moving average. The market capitalization of the company currently stands at $561.35B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 5 rate the stock a hold while 19 rate it a buy. Brokers who have rated the stock have averaged $626.17 as their price target over the next twelve months.
With the price target of $535, Deutsche Bank recently initiated with Hold rating for Lilly(Eli) & Co (NYSE: LLY).
In other news, Zakrowski Donald A, SVP, Finance, & CAO sold 670 shares of the company’s stock on Nov 06. The stock was sold for $382,637 at an average price of $571.10. Upon completion of the transaction, the SVP, Finance, & CAO now directly owns 4,708 shares in the company, valued at $2.78 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11, 10% Owner LILLY ENDOWMENT INC sold 215,000 shares of the business’s stock. A total of $130,169,879 was realized by selling the stock at an average price of $605.44. This leaves the insider owning 99,768,810 shares of the company worth $59.0 billion. Insiders disposed of 3,258,909 shares of company stock worth roughly $1.93 billion over the past 1 year. A total of 10.68% of the company’s stock is owned by insiders.
A candlestick chart of Lilly(Eli) & Co (NYSE: LLY) showed a price of $614.76 on Thursday morning. During the past 12 months, Lilly(Eli) & Co has had a low of $309.20 and a high of $629.97. As of last week, the company has a debt-to-equity ratio of 1.80, a current ratio of 1.05, and a quick ratio of 0.82. According to the stock market information, the enterprise value for the company is $579.02B, which is based on a 109.15 price-to-earnings ratio, a 4.24 price-to-earnings-growth ratio, and a beta of 0.34. The fifty day moving average price for LLY is $573.08 and a two-hundred day moving average price translates $451.25 for the stock.
The latest earnings results from Lilly(Eli) & Co (NYSE: LLY) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.11, beating analysts’ expectations of $1.98 by 0.13. This compares to $1.61 EPS in the same period last year. The net profit margin was 15.55% and return on equity was 46.86% for LLY. The company reported revenue of $9.5 billion for the quarter, compared to $6.94 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 36.84 percent. For the current quarter, analysts expect LLY to generate $8.95B in revenue.
Lilly(Eli) & Co(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
